Market closedNon-fractional
Cardiol Therapeutics/CRDL
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX
About Cardiol Therapeutics
Cardiol Therapeutics Inc is a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart diseases. The company's lead product candidate, CardiolRx, is a pharmaceutically manufactured oral cannabidiol formulation that is being clinically developed for use in heart diseases. Cardiol has received Investigational New Drug Application authorization from the United States Food and Drug Administration to conduct clinical studies to evaluate the efficacy and safety of CardiolRx in two diseases affecting the heart which are a Phase II multi-national trial, the ARCHER trial, in acute myocarditis; and a Phase II multi-center open-label pilot study in recurrent pericarditis.
Ticker
CRDL
Sector
Healthcare
Trading on
NASDAQ
Industry
Pharmaceuticals
Headquarters
Oakville, Canada
Employees
-
Website
www.cardiolrx.com
CRDL Metrics
BasicAdvanced
$156M
Market cap
-
P/E ratio
-$0.34
EPS
0.63
Beta
-
Dividend rate
Price and volume
Market cap
$156M
Beta
0.63
Financial strength
Current ratio
2.807
Quick ratio
2.646
Long term debt to equity
0.751
Total debt to equity
0.833
Management effectiveness
Return on assets (TTM)
-45.35%
Return on equity (TTM)
-92.11%
Valuation
Price to book
10.6
Price to tangible book (TTM)
10.7
Price to free cash flow (TTM)
-9.104
Growth
Earnings per share change (TTM)
0.45%
3-year earnings per share growth (CAGR)
-17.69%
What the Analysts think about CRDL
Analyst Ratings
Majority rating from 2 analysts.
CRDL Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$0
NaN%
Net income
-$9.1M
19.74%
Profit margin
0.00%
NaN%
CRDL Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.12
-$0.09
-$0.12
-$0.14
-
Expected
-$0.13
-$0.12
-$0.12
-$0.13
-$0.13
Surprise
-4.00%
-25.00%
0.00%
7.69%
-
CRDL News
AllArticlesVideos
Cardiol Therapeutics Reports Results of 2024 Annual General and Special Meeting of Shareholders
Newsfile Corp·4 weeks ago
Cardiol Therapeutics to Webcast Virtual Annual General and Special Meeting of Shareholders on June 26th at 4:30 p.m. EDT
Newsfile Corp·1 month ago
Cardiol Therapeutics releases Phase II data showing CardiolRx reduces pericarditis pain and inflammation
Proactive Investors·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Cardiol Therapeutics stock?
Cardiol Therapeutics (CRDL) has a market cap of $156M as of July 27, 2024.
What is the P/E ratio for Cardiol Therapeutics stock?
The price to earnings (P/E) ratio for Cardiol Therapeutics (CRDL) stock is 0 as of July 27, 2024.
Does Cardiol Therapeutics stock pay dividends?
No, Cardiol Therapeutics (CRDL) stock does not pay dividends to its shareholders as of July 27, 2024.
When is the next Cardiol Therapeutics dividend payment date?
Cardiol Therapeutics (CRDL) stock does not pay dividends to its shareholders.
What is the beta indicator for Cardiol Therapeutics?
Cardiol Therapeutics (CRDL) has a beta rating of 0.63. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.
Buy or sell Cardiol Therapeutics stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.